SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications. Its lead product candidate, galinpepimut-S (GPS), is a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, licensed from Memorial Sloan Kettering Cancer Center. GPS is in Phase 3 clinical trials for acute myeloid leukemia (AML) and has received Orphan Drug Designations and Fast Track designations from the FDA and EMA for AML, malignant pleural mesothelioma, and multiple myeloma. The company’s second candidate, SLS009 (tambiciclib), is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics (Shanghai), Inc. SLS009 is in Phase 2 trials for relapsed or refractory AML and has shown positive safety and efficacy data in combination with venetoclax and azacitidine. SELLAS retains rights to GPS and its next-generation candidate GPS+ outside of Greater China, where 3D Medicines Inc. holds exclusive rights. The company operates clinical trials in North America, Europe, and Asia.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage sellaslifesciences.com
Sector Healthcare IR page ir.sellaslifesciences.com/overview/default.aspx
Tags
cancer immunotherapy, acute myeloid leukemia, wt1 antigen, cdk9 inhibitor, hematologic cancers, solid tumors, peptide immunotherapy, small molecule therapeutics, clinical-stage biopharmaceutical, galinpepimut-S, GPS, SLS009, tambiciclib, GPS+, Memorial Sloan Kettering Cancer Center, 3D Medicines Inc., GenFleet Therapeutics (Shanghai) Inc., IMPACT-AML, STREAM platform
Press page —

Metrics

Valuation  
Market cap $ 2.505B
Market cap (USD) $ 2.505B
P/E -61.55
PEG —
P/BV 19.01
P/S —
P/OCF -91.79
P/FCF -88.25
Dividend yield —
Turnover / mcap —
Returns  
ROE -66.9%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 18
Quality score -61.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Revenue — — 0 1M 7.6M 1.9M — — — — — 9.319M 2.487M — — — — —
Net profit -26.863M -30.881M -37.34M -41.301M -20.699M -16.757M -19.292M -27.67M -23.754M -23.549M -63.902M -36.606M -76.678M -34.969M -11.485M -11.993M — —
Free cash flow -28.389M -35.402M -36.91M -28.309M -26.021M — — — — -44.921M -48.313M -42.926M -29.613M — -14.721M -10.363M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008
Share price 3.77 1.04 1.06 2.36 5.53 5.81 4.28 1.23 — — — — — — — — 5.58 6.24
Price performance 12m 2.63 -0.02 -0.55 -0.57 -0.05 0.36 2.48 — — — — — — — — — -0.11 -0.67

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — 0.00 — — — —
Borrowings, current (USD) 16.4M 8.38M 0.00 — — — — — — —
Borrowings, non-current (USD) — 2.61M 0.00 — — — — — — —
Lease liabilities (USD) — — 0.00 217,000 991,000 808,000 945,000 906,000 1M 1M
Cash and deposits (USD) 18.1M 2.32M 5.3M 7.28M 35.3M 21.4M 17.1M 2.53M 13.9M 71.8M
Right-of-use assets (USD) — — 0.00 217,000 896,000 723,000 874,000 858,000 925,000 963,000
Net debt (borrowings + leases - cash) (USD) -1.69M 8.67M -5.3M — — — — — — —
Cash flow detail
Operating cash flow (USD) -44.9M -11M -30.4M -17.6M -10.4M -26M -23.8M -31.4M -35.4M -28.4M
Purchases of property, plant and equipment (USD) -6,000 — — — — — — — — —
Change in payables (cash effect) (USD) -757,000 8.37M -7.94M 12,000 -836,000 -2.51M 1.21M 2.3M -2.14M -535,000
Dividends paid (cash effect) (USD) — 0.00 -487,000 0.00 — — — — — —
Interest paid (cash effect) (USD) -636,000 0.00 -321,000 0.00 — — — — — —
Income taxes paid (cash effect) (USD) — — — — — — — — 0.00 0.00
Share-based compensation (USD) 2.26M 3.17M 395,000 573,000 578,000 1.01M 1.73M 2.09M 1.56M 1.96M
Free cash flow (OCF - PPE - intangibles) (USD) -44.9M — — — — — — — — —
Income detail
Research and development expense (USD) 19.9M 6.07M 8.77M 7.29M 9.28M 15.7M 20.3M 24M 19.1M 16M
↳ 5y CAGR +11.5% -16.1% -16.1% -23.8% -17.0% -4.6% +27.3% +22.3% +21.3% +11.5%
Reported Mar 15, 2017 Mar 22, 2019 Aug 14, 2019 Mar 13, 2020 Mar 23, 2021 May 12, 2022 Mar 16, 2023 Mar 28, 2024 Mar 19, 2026 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- SELLAS to host webcast today, November 17, 2026, at 7:45 a.m. Eastern Time -

NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline results from the pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The pivotal trial evaluated GPS as maintenance monotherapy in patients who achieved a second or later complete remission (CR2 or later) or complete remission with insufficient platelet recovery (CRp2 or later) following second- or later-line salvage therapy and who were ineligible for, or unable to undergo, allogeneic stem cell transplantation.

The REGAL trial met its primary endpoint of overall survival (OS), with GPS demonstrating a statistically significant and clinically meaningful improvement in OS compared with investigator’s choice of best available treatment (BAT).

- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month -

- 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 -

- $134.7 Million in Cash and Cash Equivalents as of September 30, 2026 -

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We continue to execute across both of our clinical programs as we approach several important milestones,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS Life Sciences. “In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... Show more

NecessaryAlways Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Advertisement

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

Uncategorised

Other uncategorised cookies are those that are being analysed and have not been classified into a category as yet.

Reject All Save My Preferences Accept All

Powered by

Prompts

SELLAS Life Sciences Group, Inc. (ticker SLS), listed in United States.

Company History

Date Change Detail
Oct 23, 2017 Renamed GALENA BIOPHARMA, INC. → SELLAS LIFE SCIENCES GROUP, INC.
Sep 26, 2011 Renamed RXI PHARMACEUTICALS CORP → GALENA BIOPHARMA, INC.

ETFs Holding SELLAS Life Sciences Group, Inc.

ETF Weight in ETF Shares Market value As of
AFSM 0.31% 59,981 $ 448.058K Nov 16, 2026
ORR short -0.30% -56,413 $ -1.08M Nov 18, 2026
VFMO 0.20% 291,268 $ 3.886M Aug 31, 2026
RESM 0.09% 216 $ 3,188.16 Jun 30, 2026
MSSM 0.01% 7,651 $ 102.064K Aug 31, 2026
FSEG 0.00% 2 $ 29.52 Jun 30, 2026